ImmunoGen, Inc. (NASDAQ:IMGN) Director Mark Alan Goldberg bought 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 6th. The stock was bought at an average cost of $5.76 per share, for a total transaction of $172,800.00. Following the completion of the transaction, the director now directly owns 53,800 shares of the company’s stock, valued at approximately $309,888. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ IMGN opened at $5.93 on Friday. ImmunoGen, Inc. has a one year low of $5.24 and a one year high of $13.41. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.73 and a current ratio of 4.59. The company has a market capitalization of $919.89 million, a P/E ratio of -7.91 and a beta of 2.49.
ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings results on Friday, November 2nd. The biotechnology company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.01. ImmunoGen had a negative net margin of 176.35% and a negative return on equity of 673.66%. The firm had revenue of $10.90 million for the quarter, compared to analyst estimates of $13.60 million. During the same quarter last year, the firm posted ($0.61) earnings per share. ImmunoGen’s revenue for the quarter was up 28.2% compared to the same quarter last year. Equities research analysts predict that ImmunoGen, Inc. will post -1.24 EPS for the current year.
Several equities research analysts recently issued reports on IMGN shares. BidaskClub cut shares of ImmunoGen from a “hold” rating to a “sell” rating in a research report on Friday, July 27th. Cowen reissued a “hold” rating on shares of ImmunoGen in a research report on Friday, July 27th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of ImmunoGen in a research report on Monday, July 30th. Zacks Investment Research cut shares of ImmunoGen from a “hold” rating to a “sell” rating in a research report on Thursday, August 2nd. Finally, Piper Jaffray Companies started coverage on shares of ImmunoGen in a research report on Thursday, September 6th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $14.75.
TRADEMARK VIOLATION NOTICE: “ImmunoGen, Inc. (IMGN) Director Purchases $172,800.00 in Stock” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/10/immunogen-inc-imgn-director-purchases-172800-00-in-stock.html.
ImmunoGen Company Profile
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
See Also: Outstanding Shares
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.